Menu
Recruiting NCT06121661

APPRAISE 2.0: Live Trial of the APPRAISE Trauma Decision Support System

Phase I Interventional Wounds and Injuries

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: APPRAISE Trauma Clinical Decision Support System.
Who it may be relevant to
Registry conditions: Wounds and Injuries. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This is a pilot evaluation of the APPRAISE trauma decision-support software system ("the System"). The specific objections are as follows: 1. Evaluate the robustness of the System (i.e., whether the software performs in real-time in accordance with a priori technical specifications during real-time clinical use); 2. Evaluate whether the real-time display of the System causes distraction or confusion to clinicians treating the trauma patient such that its risks exceed its benefits; 3. Collect pilot data to allow for a statistical power analysis to design a future clinical trial evaluating efficacy.

Interventions

  • Device APPRAISE Trauma Clinical Decision Support System
    Real-time bedside decision-support system for trauma patient management

Primary outcome measures

  • Software session with error messages or critical software errors [Time frame: From patient arrival in the Emergency Department through enrollment, protocol initiation, and protocol completion (which is typically 30 min after protocol initiation).]
  • Clinician surveys that the software negatively affected patient care [Time frame: From patient arrival in the Emergency Department through enrollment, protocol initiation, and protocol completion (which is typically 30 min after protocol initiation)]
  • Clinician surveys that the software positively affected patient care [Time frame: From patient arrival in the Emergency Department through enrollment, protocol initiation, and protocol completion (which is typically 30 min after protocol initiation)]
  • Clinician surveys that ongoing use of the software poses risks that exceeds benefits [Time frame: From patient arrival in the Emergency Department through enrollment, protocol initiation, and protocol completion (which is typically 30 min after protocol initiation)]

Eligibility criteria

Inclusion criteria

  • Adult (≥18 yrs) Emergency Department (ED) patient
  • Triaged to the "Acute" area of the ED. (The "Acute" area is the designated area for ED patients with potential or established critical illness. Triage to Acute is a routine ED operation that is performed based on departmental guidelines and the professional judgement of an experienced triage nurse).
  • Clinical concern for acute injury (based on either an explicitly chief complaint of acute injury, or clinical team with documented concern for acute injury as a relevant part of patient presentation).

Exclusion criteria

  • Prisoners
  • Patients known to be pregnant, based on patient report, physical exam, or bedside ultrasound
  • Patients wearing an "EFIC Opt-Out" bracelet
  • Any concern about the suitability of the software system for a specific patient by any clinician involved in the patient's ED care, or by the patient themselves (or by any LAR \[lawfully authorized representative\] of the patient).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Device feasibility

Study locations

United States · 1 center
  • Massachusetts General Hospital — Boston

Identifiers

NCT: NCT06121661 · 2022P001136

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗